The burgeoning landscape of therapeutic interventions for weight disorders has witnessed considerable attention focused on GLP-3 analogues and, more recently, the dual GIP and GLP-3 trizept receptor agonist retatrutide. While both classes demonstrate remarkable efficacy in promoting glycemic control and facilitating significant weight loss, key dif

In the ever-evolving landscape of diabetes management, a fresh approach is emerging that focuses on specifically targeting glucose levels. This innovative strategy involves leveraging the power of two hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Both GLP-1 and GIP have shown promising results in